| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_0acc7fd312a68983fb8b9d120043467e |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-53
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-506
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-502
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-235
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K33-243
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-65 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-235
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-506
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-53
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-65
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K33-243 |
| filingDate |
2019-10-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_11e6588e8403e90bf2ff59450cb6454d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5965f0d7334da42d68edc3e6758d0526 |
| publicationDate |
2021-12-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2021386750-A1 |
| titleOfInvention |
Methods and materials for treating cancer |
| abstract |
This document provides methods and materials involved in treating mammals having cancer. For example, a mammal having a breast cancer 1 (BRCA1)-deficient cancer and/or a nicotinamide N-methyltransferase (NNMT) overexpressing cancer can be treated by administering one or more agents that can inhibit mitochondrial metabolism (e.g., one or more oxidative phosphorylation (OXPHOS) inhibitors and/or one or more inhibitors of a mitochondrial polypeptide) and/or one or more agents that can inhibit glucose transport (e.g., one or more inhibitors of a glucose transporter polypeptide such as glucose transporter 1 (GLUT1)) to the mammal. In some cases, one or more OXPHOS inhibitors can be administered to a mammal having a BRCA1-deficient cancer and/or a NNMT overexpressing cancer in combination with one or more poly(ADP-ribose) polymerase (PARP) inhibitors and/or one or more platinum compounds. |
| priorityDate |
2018-10-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |